摘要
目的探究血清降钙素原(PCT)在慢性肺源性心脏病急性加重期(AECPHD)治疗中临床应用价值。方法入选424例AECPHD患者,随机分成PCT治疗组(n=210)和常规治疗组(n=214)。主要观察指标为抗生素的使用时间、住院天数、临床有效率、病情加重例数以及死亡例数等。结果 PCT治疗组在抗生素使用时间、住院天数及二重感染发生例数等方面均少于常规治疗组,具有统计学差异;两组患者在临床有效率、死亡率、加重例数方面无统计学差异。结论在AECPHD治疗中参考血清PCT水平使用抗生素抗感染治疗可达到有效治疗效果,缩短抗菌治疗时间,避免了过度使用抗生素。
Objective To explore the application value of serum procalcitonin （PCT） in the treatment of pa- tients with acute exacerbation of chronic pulmonary heart disease （AECPHD）. Methods 424 patients with AECPHD were randomly divided into the PCT group （n =210） and the control group （n =214）. The main observa- tion indexes included the days of antibiotics use, duration of hospital stay, clinical efficacy, aggravated cases and mortality. Results The time of antibiotic use, duration of hospital stay and double infection cases were less in the PCT group than in the control group. There was no significant difference on total clinical effective rate, mortality and aggravated cases between the two groups. Conclusion The antibiotics use based on PCT level is effective in the treatment of patents with AECPHD, which can shorten the duration of antibiotics use and reduce the unnecessary anti- biotic exposure.
出处
《临床肺科杂志》
2014年第2期300-302,共3页
Journal of Clinical Pulmonary Medicine
关键词
慢性肺源性心脏病
降钙素原
抗菌治疗
chronic pulmonary heart disease
procalcitonin
antibiotic therapy
